We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Sarepta CRL Shines Light on FDA’s Review of DMD Treatment
Sarepta CRL Shines Light on FDA’s Review of DMD Treatment
A routine document released by the FDA on Wednesday raised new questions about the agency’s rejection — and subsequent approval — of Sarepta’s Duchenne muscular dystrophy (DMD) treatment Vyondys 53.